{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:39:50Z","timestamp":1792391990333,"version":"4.4.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.carrev.2018.05.021","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T12:09:46Z","timestamp":1527941386000},"page":"351-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cellular and molecular approaches to enhance myocardial recovery after myocardial infarction"],"prefix":"10.1016","volume":"20","author":[{"given":"Yasir","family":"Parviz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Waleed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sethumadhavan","family":"Vijayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahar","family":"Lavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Al Nooryani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javaid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2018.05.021_bb0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jacc.2010.05.008","article-title":"Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention","volume":"56","author":"Roe","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ncpcardio1371","article-title":"Myocardial protection: is primary PCI enough?","volume":"6","author":"Hausenloy","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.carrev.2018.05.021_bb0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.carrev.2017.02.004","article-title":"A review of strategies for infarct size reduction during acute myocardial infarction","volume":"18","author":"Parviz","year":"2017","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI62874","article-title":"Myocardial ischemia-reperfusion injury: a neglected therapeutic target","volume":"123","author":"Hausenloy","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.carrev.2018.05.021_bb0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cvr\/cvr271","article-title":"The coronary circulation in cardioprotection: more than just one confounder","volume":"94","author":"Heusch","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0035","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1111\/bph.13013","article-title":"Role of the MPTP in conditioning the heart - translatability and mechanism","volume":"172","author":"Ong","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0040","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1017\/S0029665199001317","article-title":"An overview of methods for assessment of free radical activity in biology","volume":"58","author":"Jackson","year":"1999","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.carrev.2018.05.021_bb0045","first-page":"H1269","article-title":"Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury","volume":"255","author":"Granger","year":"1988","journal-title":"Am J Physiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0050","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.005975","article-title":"Activation of cGMP\/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling","volume":"2","author":"Inserte","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2018.05.021_bb0055","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00395-011-0225-5","article-title":"The role of mitochondrial permeability transition in reperfusion-induced cardiomyocyte death depends on the duration of ischemia","volume":"106","author":"Ruiz-Meana","year":"2011","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.carrev.2018.05.021_bb0065","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0070","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1161\/CIRCULATIONAHA.109.916346","article-title":"Monocytes: protagonists of infarct inflammation and repair after myocardial infarction","volume":"121","author":"Nahrendorf","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.1230719","article-title":"Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure","volume":"339","author":"Swirski","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.carrev.2018.05.021_bb0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.297.1.43","article-title":"Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial","volume":"297","author":"Armstrong","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2018.05.021_bb0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2008.12.017","article-title":"Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results of the F.I.R.E. (efficacy of FX06 in the prevention of myocardial reperfusion injury) trial","volume":"53","author":"Atar","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0090","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.CIR.0000087447.12918.85","article-title":"Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial","volume":"108","author":"Granger","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcmg.2009.09.014","article-title":"Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial","volume":"3","author":"Patel","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.carrev.2018.05.021_bb0100","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.carrev.2018.05.021_bb0110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0115","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/01.CIR.78.6.1449","article-title":"Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury","volume":"78","author":"Crawford","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcmg.2009.10.006","article-title":"Myocardial infarct size reduction with Pexelizumab: the role of chance is patently clear","volume":"3","author":"Gibson","year":"2010","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.carrev.2018.05.021_bb0125","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1097\/01.CCM.0000269035.30231.76","article-title":"The fibrin-derived peptide Bbeta15-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury","volume":"35","author":"Roesner","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/SHK.0b013e31802fa038","article-title":"The effects of the fibrin-derived peptide Bbeta(15-42) in acute and chronic rodent models of myocardial ischemia-reperfusion","volume":"27","author":"Zacharowski","year":"2007","journal-title":"Shock"},{"key":"10.1016\/j.carrev.2018.05.021_bb0135","article-title":"COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response","volume":"3","author":"Akodad","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.carrev.2018.05.021_bb0140","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/heartjnl-2015-308542","article-title":"Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis","volume":"102","author":"Hemkens","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2018.05.021_bb0145","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJMoa012295","article-title":"Widespread coronary inflammation in unstable angina","volume":"347","author":"Buffon","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0155","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.carrev.2018.05.021_bb0160","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/01.ATV.16.8.1000","article-title":"Interleukin-1 beta in coronary arteries of patients with ischemic heart disease","volume":"16","author":"Galea","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0165","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ahj.2004.10.025","article-title":"Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis","volume":"150","author":"Satterthwaite","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0170","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2353\/ajpath.2006.051054","article-title":"Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice","volume":"168","author":"Chamberlain","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1749-6632.1993.tb49932.x","article-title":"Role of cytokines in infection-induced stress","volume":"697","author":"Dunn","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.carrev.2018.05.021_bb0180","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1749-6632.1997.tb51734.x","article-title":"Interleukin-1 and defensins in thermoregulation, stress, and immunity","volume":"813","author":"Korneva","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.carrev.2018.05.021_bb0185","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/01.ATV.16.8.1000","article-title":"Interleukin-1\u03b2 in coronary arteries of patients with ischemic heart disease","volume":"16","author":"Galea","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000106","article-title":"Interleukin-1beta blockade improves left ventricular systolic\/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse","volume":"64","author":"Toldo","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0195","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/737585","article-title":"Impact of an interleukin-1 receptor antagonist and erythropoietin on experimental myocardial ischemia\/reperfusion injury","volume":"2012","author":"Grothusen","year":"2012","journal-title":"ScientificWorldJournal"},{"issue":"11","key":"10.1016\/j.carrev.2018.05.021_bb0200","first-page":"828","article-title":"The selective NLRP3- inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","volume":"38","author":"van Hout","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0205","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0210","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1749-6632.1970.tb49786.x","article-title":"Mitochondrial responses to carbon monoxide toxicity","volume":"174","author":"Chance","year":"1970","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.carrev.2018.05.021_bb0215","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0091-7435(79)90008-2","article-title":"Mechanisms of carbon monoxide toxicity","volume":"8","author":"Coburn","year":"1979","journal-title":"Prev Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0220","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.jacc.2005.01.044","article-title":"Cardiovascular manifestations of moderate to severe carbon monoxide poisoning","volume":"45","author":"Satran","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0225","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0196-0644(89)80516-5","article-title":"Complications and protocol considerations in carbon monoxide-poisoned patients who require hyperbaric oxygen therapy: report from a ten-year experience","volume":"18","author":"Sloan","year":"1989","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0100-879X1999000100001","article-title":"Carbon monoxide: from toxin to endogenous modulator of cardiovascular functions","volume":"32","author":"Johnson","year":"1999","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0235","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/ki.2010.542","article-title":"Carbon monoxide-releasing molecules protect against ischemia-reperfusion injury during kidney transplantation","volume":"79","author":"Caumartin","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.carrev.2018.05.021_bb0240","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-230X-10-42","article-title":"Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats","volume":"10","author":"Wei","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0245","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/74680","article-title":"Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway","volume":"6","author":"Otterbein","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/bja\/aep087","article-title":"Protective effects of inhaled carbon monoxide in pig lungs during cardiopulmonary bypass are mediated via an induction of the heat shock response","volume":"103","author":"Goebel","year":"2009","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.carrev.2018.05.021_bb0255","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1161\/hh0202.104530","article-title":"Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities","volume":"90","author":"Motterlini","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0260","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00134-008-1011-1","article-title":"Use of carbon monoxide as a therapeutic agent: promises and challenges","volume":"34","author":"Foresti","year":"2008","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0265","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/01.RES.0000084381.86567.08","article-title":"Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule","volume":"93","author":"Clark","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0270","doi-asserted-by":"crossref","first-page":"H1649","DOI":"10.1152\/ajpheart.00971.2003","article-title":"Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo","volume":"286","author":"Guo","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0275","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1161\/CIRCULATIONAHA.109.905471","article-title":"Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart","volume":"121","author":"Wang","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yjmcc.2004.10.006","article-title":"Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction","volume":"38","author":"Stein","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0285","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05911","article-title":"Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls","volume":"447","author":"Wellcome Trust Case Control C","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.carrev.2018.05.021_bb0290","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/01.CIR.0000143041.58692.CC","article-title":"Genetic basis of atherosclerosis: part I: new genes and pathways","volume":"110","author":"Lusis","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.2480","article-title":"Large-scale association analysis identifies new risk loci for coronary artery disease","volume":"45","author":"CAD","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.carrev.2018.05.021_bb0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H","article-title":"Gene directed enzyme\/prodrug therapy of cancer: historical appraisal and future prospectives","volume":"187","author":"Greco","year":"2001","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0305","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2967\/jnumed.106.037598","article-title":"PET measurements of myocardial glucose metabolism with 1-11C-glucose and kinetic modeling","volume":"48","author":"Herrero","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0310","doi-asserted-by":"crossref","first-page":"11694","DOI":"10.1073\/pnas.0704820104","article-title":"Probing genetic overlap among complex human phenotypes","volume":"104","author":"Rzhetsky","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.carrev.2018.05.021_bb0315","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/heartjnl-2013-304845","article-title":"The effect of cyclosporin-a on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial","volume":"100","author":"Hausenloy","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2018.05.021_bb0320","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJMoa071142","article-title":"Effect of cyclosporine on reperfusion injury in acute myocardial infarction","volume":"359","author":"Piot","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0325","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jacc.2009.10.052","article-title":"Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction","volume":"55","author":"Mewton","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0330","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1111\/j.1476-5381.2011.01691.x","article-title":"Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis","volume":"165","author":"Lim","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0335","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa1505489","article-title":"Cyclosporine before PCI in patients with acute myocardial infarction","volume":"373","author":"Cung","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0340","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jacc.2015.10.081","article-title":"Cyclosporine a in Reperfused myocardial infarction: The Multicenter, Controlled, Open-Label CYCLE Trial","volume":"67","author":"Ottani","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0345","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1161\/CIRCRESAHA.112.265942","article-title":"Physiological roles of the permeability transition pore","volume":"111","author":"Brenner","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0350","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1161\/01.CIR.0000151290.04952.3B","article-title":"Postconditioning inhibits mitochondrial permeability transition","volume":"111","author":"Argaud","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0355","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1161\/CIRCULATIONAHA.105.540468","article-title":"Letter regarding article by Argaud et al, \"postconditioning inhibits mitochondrial permeability transition\"","volume":"111","author":"Facundo","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0360","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejcts.2004.08.032","article-title":"Na+\/H+ exchange inhibition in hypertrophied myocardium subjected to cardioplegic arrest: an effective cardioprotective approach","volume":"27","author":"Kevelaitis","year":"2005","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.carrev.2018.05.021_bb0365","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/01.CIR.101.25.2902","article-title":"Cardioprotective effects of the Na+\/H+ exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA","volume":"101","author":"Rupprecht","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0370","first-page":"1515","article-title":"Na+\/H+ exchange inhibition with HOE 642 improves recovery of the injured neonatal rabbit heart","volume":"19","author":"Sett","year":"2003","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0375","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0735-1097(01)01608-4","article-title":"The Na+\/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial","volume":"38","author":"Zeymer","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0380","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1093\/eurheartj\/ehl304","article-title":"Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: the randomized multicentre CASTEMI study","volume":"27","author":"Bar","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0385","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/eurheartj\/ehu331","article-title":"Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results","volume":"36","author":"Atar","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0390","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ahj.2012.12.008","volume":"165","author":"Chakrabarti","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0395","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1093\/eurheartj\/ehu177","article-title":"Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI randomized controlled trial","volume":"35","author":"Lincoff","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0400","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1161\/ATVBAHA.115.305655","article-title":"Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction","volume":"35","author":"Ye","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0405","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1160\/TH11-12-0867","article-title":"Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse","volume":"107","author":"Totani","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.carrev.2018.05.021_bb0410","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2044.2009.06008.x","article-title":"A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery","volume":"64","author":"De Hert","year":"2009","journal-title":"Anaesthesia"},{"key":"10.1016\/j.carrev.2018.05.021_bb0415","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00000542-200408000-00009","article-title":"Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration","volume":"101","author":"De Hert","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.carrev.2018.05.021_bb0420","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1017\/S0265021506001931","article-title":"Cardiac protection by volatile anaesthetics: a multicentre randomized controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass","volume":"24","author":"Tritapepe","year":"2007","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0425","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.jvca.2010.03.002","article-title":"Myocardial protection with isoflurane during off-pump coronary artery bypass grafting: a randomized trial","volume":"25","author":"Tempe","year":"2011","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.carrev.2018.05.021_bb0430","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1089253210376839","article-title":"Cardiac protection during on-pump coronary artery bypass grafting: ischemic versus isoflurane preconditioning","volume":"14","author":"Amr","year":"2010","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.carrev.2018.05.021_bb0435","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1161\/CIRCINTERVENTIONS.112.968388","article-title":"Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia","volume":"5","author":"Lonborg","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.05.021_bb0440","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/jama.2011.592","article-title":"Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial","volume":"305","author":"Najjar","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2018.05.021_bb0445","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0735-1097(99)00418-0","article-title":"Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial","volume":"34","author":"Mahaffey","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0450","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.jacc.2005.02.061","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II)","volume":"45","author":"Ross","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0455","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCINTERVENTIONS.109.858977.109.858977","article-title":"Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial","volume":"2","author":"Fokkema","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.05.021_bb0460","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehu096","article-title":"Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI)","volume":"35","author":"Siddiqi","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0465","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCRESAHA.116.305082","article-title":"Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction","volume":"116","author":"Jones","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0470","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.05.021_bb0475","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0735-1097(94)00462-Y","article-title":"Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience","volume":"25","author":"Tan","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0480","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(07)61634-1","article-title":"Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials","volume":"370","author":"Kitakaze","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.05.021_bb0485","doi-asserted-by":"crossref","first-page":"H1654","DOI":"10.1152\/ajpheart.01378.2006","article-title":"Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice","volume":"293","author":"Gomez","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0490","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cardiores.2006.12.011","article-title":"Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage","volume":"73","author":"Ikeno","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0495","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1161\/01.CIR.0000101682.24138.36","article-title":"Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo","volume":"108","author":"Inagaki","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0500","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0735-1097(02)02115-0","article-title":"Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor","volume":"40","author":"Jones","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0505","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.109.853267","article-title":"Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I","volume":"120","author":"Dezfulian","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0510","doi-asserted-by":"crossref","first-page":"10256","DOI":"10.1073\/pnas.0801336105","article-title":"Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury","volume":"105","author":"Hendgen-Cotta","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.carrev.2018.05.021_bb0515","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejphar.2008.02.057","article-title":"Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat","volume":"586","author":"Zhou","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2014.09.038","article-title":"Erythropoietin protects myocardium against ischemia-reperfusion injury under moderate hyperglycemia","volume":"745","author":"Jun","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151025","article-title":"Morphine-induced preconditioning: involvement of protein kinase a and mitochondrial permeability transition pore","volume":"11","author":"Dorsch","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.carrev.2018.05.021_bb0530","doi-asserted-by":"crossref","first-page":"129612","DOI":"10.1155\/2015\/129612","article-title":"Morphine reduces myocardial infarct size via heat shock protein 90 in rodents","volume":"2015","author":"Small","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.carrev.2018.05.021_bb0535","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/EJA.0b013e32832c785d","article-title":"Tramadol reduces myocardial infarct size and expression and activation of nuclear factor kappa B in acute myocardial infarction in rats","volume":"26","author":"Zhang","year":"2009","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0540","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00395-009-0078-3","article-title":"Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative\/nitrosative stress attenuation","volume":"105","author":"Iliodromitis","year":"2010","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0545","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/01.CIR.85.2.659","article-title":"Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction","volume":"85","author":"Thornton","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0550","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00395-006-0587-2","article-title":"Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts","volume":"101","author":"Yang","year":"2006","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0555","first-page":"BR155","article-title":"Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat","volume":"9","author":"Wayman","year":"2003","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.carrev.2018.05.021_bb0560","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0008-6363(96)88579-8","article-title":"Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion","volume":"29","author":"Scholz","year":"1995","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0565","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1074248413508003","article-title":"Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia","volume":"19","author":"Brown","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.carrev.2018.05.021_bb0570","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.yjmcc.2004.12.001","article-title":"Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury","volume":"38","author":"Argaud","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0575","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.CIR.83.1.237","article-title":"Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period","volume":"83","author":"Pitarys","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0580","first-page":"35","article-title":"Effect of magnesium on infarct size after coronary occlusion. Animal experiment studies","volume":"1","author":"Thamer","year":"1997","journal-title":"Herz"},{"key":"10.1016\/j.carrev.2018.05.021_bb0585","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cardiores.2003.11.012","article-title":"Selective retroinfusion of GSH and cariporide attenuates myocardial ischemia-reperfusion injury in a preclinical pig model","volume":"61","author":"Kupatt","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0590","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.RES.0000122392.33172.09","article-title":"Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts","volume":"94","author":"Gross","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0595","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1124\/jpet.108.138008","article-title":"Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3 beta, SB216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione], via inhibition of the mitochondrial permeability transition pore","volume":"326","author":"Obame","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.carrev.2018.05.021_bb0600","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005426","article-title":"Cardioprotective effects of intracoronary morphine in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a prospective, randomized trial","volume":"6","author":"Gwag","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2018.05.021_bb0605","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00000542-200001000-00038","article-title":"Approaches to the prevention of perioperative myocardial ischemia","volume":"92","author":"Warltier","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1016\/j.carrev.2018.05.021_bb0610","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s12630-015-0456-2","article-title":"One-year outcome of the sevoflurane in acute myocardial infarction randomized trial","volume":"62","author":"Lavi","year":"2015","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.carrev.2018.05.021_bb0615","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1399-6576.1995.tb04098.x","article-title":"Effects of sevoflurane on ischaemic myocardium in dogs","volume":"39","author":"Takahata","year":"1995","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.carrev.2018.05.021_bb0620","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"Lonborg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0625","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0630","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2013.11.007","article-title":"Progression in attenuating myocardial reperfusion injury: an overview","volume":"170","author":"Bernink","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0635","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0640","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/01.RES.0000170229.49776.81","article-title":"HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size","volume":"96","author":"Yamakuchi","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0645","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1253\/circj.70.1643","article-title":"Early administration of fluvastatin, but not at the onset of ischemia or reperfusion, attenuates myocardial ischemia-reperfusion injury through the nitric oxide pathway rather than its antioxidant property","volume":"70","author":"Matsuki","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0650","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1161\/01.RES.47.6.807","article-title":"The role of adenosine in the regulation of coronary blood flow","volume":"47","author":"Berne","year":"1980","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0655","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/01.RES.56.4.517","article-title":"Role of adenosine in coronary blood flow regulation after reductions in perfusion pressure","volume":"56","author":"Dole","year":"1985","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0660","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1161\/01.CIR.92.9.2617","article-title":"Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model","volume":"92","author":"Christensen","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0665","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(02)11278-5","article-title":"Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the magnesium in coronaries (MAGIC) trial: a randomised controlled trial","volume":"360","author":"Magnesium in Coronaries Trial I","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.05.021_bb0670","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1161\/CIRCULATIONAHA.107.748814","article-title":"Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction","volume":"117","author":"Gonzalez","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0675","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11010-006-2518-9","article-title":"Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts","volume":"283","author":"Gambert","year":"2006","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.carrev.2018.05.021_bb0680","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0685","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000369246","article-title":"Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function in a Swine model of coronary microembolization","volume":"130","author":"Liu","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.carrev.2018.05.021_bb0690","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/oxfordjournals.eurheartj.a060322","article-title":"Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine","volume":"13","author":"Kober","year":"1992","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0695","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/hrt.2006.107524","article-title":"Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention","volume":"93","author":"Bonello","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2018.05.021_bb0700","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00129784-200505040-00006","article-title":"Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study","volume":"5","author":"El-Kady","year":"2005","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.carrev.2018.05.021_bb0705","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1053\/euhj.1999.2439","volume":"21","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0710","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/euhj.2000.2528","article-title":"The EMIP-FR study: the evolution of scientific background as a non-controlled parameter","volume":"22","author":"Grynberg","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0715","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/eurheartj\/ehv597","article-title":"EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention","volume":"37","author":"Gibson","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0720","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/B:APPT.0000038035.75845.ab","article-title":"Early anti-apoptosis treatment reduces myocardial infarct size after a prolonged reperfusion","volume":"9","author":"Gao","year":"2004","journal-title":"Apoptosis"},{"key":"10.1016\/j.carrev.2018.05.021_bb0725","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7150\/ijms.4514","article-title":"MicroRNA 21 inhibits left ventricular remodeling in the early phase of rat model with ischemia-reperfusion injury by suppressing cell apoptosis","volume":"9","author":"Qin","year":"2012","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.carrev.2018.05.021_bb0730","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1161\/01.CIR.0000034046.87607.1C","article-title":"Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans","volume":"106","author":"Strauer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0735","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1161\/01.CIR.0000043246.74879.CD","article-title":"Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI)","volume":"106","author":"Assmus","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0740","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/01.RES.0000144798.54040.ed","article-title":"Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction","volume":"95","author":"Fernandez-Aviles","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0745","doi-asserted-by":"crossref","first-page":"I178","DOI":"10.1161\/CIRCULATIONAHA.104.522292","article-title":"Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety","volume":"112","author":"Bartunek","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0750","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjcard.2004.03.034","article-title":"Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction","volume":"94","author":"Chen","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2018.05.021_bb0755","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(04)16626-9","article-title":"Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial","volume":"364","author":"Wollert","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.05.021_bb0760","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0140-6736(05)67861-0","article-title":"Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial","volume":"367","author":"Janssens","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.05.021_bb0765","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa055706","article-title":"Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction","volume":"355","author":"Lunde","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0770","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa060186","article-title":"Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction","volume":"355","author":"Schachinger","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.05.021_bb0775","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1093\/eurheartj\/ehl401","article-title":"Reduction in infarct size, but no functional improvement after bone marrow cell administration in a porcine model of reperfused myocardial infarction","volume":"27","author":"Moelker","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.021_bb0780","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCRESAHA.112.300730","article-title":"Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function","volume":"113","author":"Houtgraaf","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.021_bb0785","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCULATIONAHA.112.131110","article-title":"Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction","volume":"127","author":"Williams","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.021_bb0790","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089979","article-title":"Epigenetic upregulation of endogenous VEGF-A reduces myocardial infarct size in mice","volume":"9","author":"Turunen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.carrev.2018.05.021_bb0795","first-page":"135","article-title":"Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction","volume":"12","author":"Zhou","year":"2015","journal-title":"J Geriatr Cardiol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918302434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918302434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:15:30Z","timestamp":1761560130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838918302434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":159,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1553838918302434"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2018.05.021","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and molecular approaches to enhance myocardial recovery after myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2018.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}